NCT03231709View on ClinicalTrials.gov

Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 18, 2017

Primary Completion Date

February 9, 2018

Study Completion Date

February 9, 2018

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Trelagliptin

Trelagliptin tablets

DRUG

Alogliptin

Alogliptin tablets

Trial Locations (2)

Unknown

OCROM Clinic, Suita

ToCROM Clinic, Shinjuku

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT03231709 - Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter